Non-small-cell lung carcinoma (NSCLC)


Non-small-cell lung carcinoma (NSCLC)

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both pre-operatively (neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy).

The most common types of NSCLC in the United States include Adenocarcinoma/bronchoalveolar, Bronchoalveolar, Squamous cell carcinoma and Large-cell carcinoma.

Staging of NSCLC
NSCLC has four stages, designated I, II, III, and IV.
Stage I: Tumors are limited to the lung.
Stage II: Tumors have spread to lymph nodes or airways at the root of the lung or to the external lining of the lung.
Stage III: means that the cancer has spread to the lymph nodes in the middle of the chest or above the collarbones (supraclavicular nodes) and/or spread to adjacent organs or tissues.
Stage IV: Tumors have spread to the other lung or to distant sites within the body.

Prognosis, Life Expectancy, and Survival Rate for Non-Small-Cell Lung Cancer
Overall, 14% of people with NSCLC survive for at least five years. People who have stage I NSCLC and undergo surgery have a 70% chance of surviving five years. People with extensive inoperable NSCLC have an average survival duration of nine months. A person with small-cell lung cancer who functions well has an advantage over someone who cannot work or pursue normal activities.

Complications of NSCLC
NSCLC include many complications to patient who survive. These include Spinal cord compression, Bone pain, Hormone or electrolyte imbalances, Problems with mental functioning or concentration, Visual problems, Liver failure, Pain in right side from enlarged liver, Weight loss, Severe hemoptysis (coughing up blood).

Journal of Oncology Translational Research with ISSN number: 2476-2261 is a peer reviewed online open access journal seeking to publish articles that includes a wide range of topics in this field and creates a platform for the authors to make their contribution towards the journal. The journal covers all aspects of modern research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients and creates a platform for the authors to contribute towards the journal.
The authors may forward the manuscript as an email attachment whereby the editorial office takes care of the further processing.
To submit manuscript online please click here: translational-research.html
To send as attachment, email to: or

Media contact,
Jessica Rose
Journal of Oncology Translational Research
Whatsapp no: +1-947-333-4405